Medicover AB (publ)

Medicover AB (publ)

MCVEF
Medicover AB (publ)US flagOther OTC
27.25
USD
- -
- -
4.11BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.74
3.12
5.23
4.87
5.04
6.33
7.04
9.28
10.16
11.69
13.95
15.78
15.03
Basic EPS, GAAP
0.03
0.06
0.05
0.16
0.17
0.17
0.18
0.69
0.08
0.12
0.11
0.51
0.29
Free Cash Flow per Basic Share
-0.01
-0.02
-0.87
0.18
-0.06
-0.29
0.58
0.77
0.2
0.63
0.93
1.23
1.05
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
0.07
0.12
0.12
0.12
0.15
0.15
Book Value per Share
0.46
0.52
0.84
0.09
0.25
0.39
0.57
1.16
1.04
1.07
0.69
1.08
0.81
Tangible Book Value per Share
-0.16
-0.24
-0.54
1.15
0.87
-0.09
0.92
0.78
-0.76
-0.74
-1.12
-1.78
-2.11
Basic Weighted Avg Shares
133
133
95
119
133
133
142
148
149
149
150
151
150
Sales/Revenue/Turnover
365
416
497
580
672
844
998
1,377
1,510
1,746
2,092
2,378
2,258
Operating Margin (%)
4.6
5.17
4.24
4.96
5.02
5.54
6.59
11.57
3.75
3.5
4.14
6.55
4.77
Depreciation Expense
18
18
23
26
57
74
96
111
162
183
198
215
222
Net Income, GAAP
4
8
4
19
22
22
26
102
12
18
17
78
43
Effective Tax Rate (%)
63.57
46.11
47.15
27.86
23.66
25.83
26.81
25.87
29.74
22.03
27.36
26.12
28.31
Profit Margin (%)
1.18
1.8
0.86
3.22
3.32
2.66
2.59
7.39
0.78
1.01
0.8
3.26
1.92
Working Capital
-72
39
37
36
59
-66
61
227
-22
-119
-120
-211
-69
LT Debt
- -
126
195
138
223
306
318
675
838
775
981
1,095
1,187
Total Equity
90
93
99
300
318
360
484
562
508
528
489
545
485
Return on Invested Capital (%)
- -
5.46
4.12
5.24
4.87
4.98
5.75
10.68
2.82
3.16
3.83
6.13
4.29
Return on Capital (%)
- -
4.11
1.82
8.58
11.51
7.25
7.29
15.28
3.23
4.89
4.8
8.69
6.52
Return on Common Equity (%)
- -
11.51
5.79
41.19
99.33
52.39
38.77
80.57
7.22
11.19
12.68
58.03
31.61

Capital Structure

FRC

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
258
248
237
LT Borrowings
543
560
746
LT Finance Leases
438
437
441
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
150
150
151
Market Capitalization
2,179
2,498
2,528

Working Capital

FRC

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
447
481
477
Cash, Cash Equivalents & STI
83
113
89
Accounts Receivable, Net
212
306
329
Inventories
69
62
59
Total Current Liabilities
566
565
546
Payables & Accruals
- -
- -
- -
ST Debt
258
248
237
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
27.76%
2.92%
11.36%
Free Cash Flow
394.41%
52.88%
32.95%
Net Income, GAAP
94.13%
122.85%
364.07%
Sales/Revenue/Turnover
19.28%
19.36%
13.69%
Total Cash Common Dividend
- -
- -
25%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
499
509
528
556
2,092
2025
578
597
612
- -
2,378
2026
624
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.04
-0.03
0.06
0.11
2025
0.13
0.13
0.12
- -
0.51
2026
0.15
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.12
- -
- -
0.12
2025
- -
0.15
- -
- -
0.15
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
John Paul Stubbington
Full Time Employees
49,000
Sector
Healthcare
Industry
Medical - Care Facilities
Address
Riddargatan 12A Stockholm AB Sweden 102 46
IPO Date
Aug 28, 2019
Business
Medicover AB (publ) (MCOV B; MCVEF) operates as an international healthcare and diagnostic services provider, offering a comprehensive range of medical and diagnostic solutions through its two primary divisions: Healthcare Services, which encompasses primary care, specialist outpatient and inpatient care, hospitals, ambulatory clinics, specialty-care facilities, fertility treatment, state-of-the-art dental services, optician services, wellbeing solutions including sports packages and diets, and fitness clubs; and Diagnostic Services, which provides laboratory testing across clinical pathology areas such as allergy and autoimmune diagnostics, bacteriology, parasitology, biochemistry and immunochemistry, blood group diagnostics, tumour markers, clinical chemistry, cytology, haematology, histopathology, human genetics, hygiene, immunology, infectious diseases, microbiology, molecular biology, and pharmacology/toxicology. The company serves corporate clients, individuals, public payers, healthcare professionals, and hospitals via an extensive network of clinics, hospitals, laboratories, and blood-drawing points in over 20 countries, with primary operations in Central and Eastern Europe including Poland, Germany, Romania, Ukraine; India; the Nordic countries; and recent expansions into Turkey, Cyprus, Slovenia, Croatia, and North Macedonia. Founded in 1995 and headquartered in Stockholm, Sweden, Medicover maintains a presence in 23 countries and employs over 44,000 staff. Recent developments include the April 2025 acquisition of SYNLAB Group's operations in Romania, Turkey, Cyprus, Slovenia, Croatia, and North Macedonia for EUR 71.3 million, adding 25 laboratories, 80 collection centers, and 675 employees to enhance diagnostic capabilities and enter three new markets; the completion of the CityFit fitness club operator acquisition in Poland in April 2025 for approximately SEK 1.4 billion (PLN 565 million), expanding its wellness offerings to over 170 clubs; plans to open two new hospitals in India in 2025 and early 2026 alongside evaluation of a potential separate listing of its Indian hospital subsidiary; and the appointment of John Stubbington as new CEO effective May 1, 2025.

Company News

APIChatGPT
  • Medicover AB (publ) (MCVEY) Q1 2026 Earnings Call Transcript